Related references
Note: Only part of the references are listed.Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys
Patricia J. Masarachia et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Five Years of Continued Therapy in a Phase 2 Study
Bente Langdahl et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib
Thomas M. Ruenger et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism
Yasuo Ochi et al.
BONE (2011)
The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking
P. Leung et al.
BONE (2011)
Denosumab and bisphosphonates: Different mechanisms of action and effects
Roland Baron et al.
BONE (2011)
Pharmacokinetics and Metabolism in Rats, Dogs, and Monkeys of the Cathepsin K Inhibitor Odanacatib: Demethylation of a Methylsulfonyl Moiety as a Major Metabolic Pathway
Kelem Kassahun et al.
DRUG METABOLISM AND DISPOSITION (2011)
Glucocorticoid dose determines osteocyte cell fate
Junjing Jia et al.
FASEB JOURNAL (2011)
Cathepsin K Inhibitors Prevent Bone Loss in Estrogen-Deficient Rabbits
Brenda L. Pennypacker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Three-Year Continued Therapy and Resolution of Effect
John A. Eisman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Safety and Efficacy of the Cathepsin K Inhibitor ONO-5334 in Postmenopausal Osteoporosis: The OCEAN Study
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis
Aline G. Costa et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys
C. Jerome et al.
OSTEOPOROSIS INTERNATIONAL (2011)
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor
Elise Isabel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Osteoporosis: impact on health and economics
Nicholas Harvey et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Of mice and men: divergent risks of teriparatide-induced osteosarcoma
V. Subbiah et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools
Sylvie Desmarais et al.
BIOLOGICAL CHEMISTRY (2009)
Bone density, strength, and formation in adult cathepsin K (-/-) mice
B. Pennypacker et al.
BONE (2009)
Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys
G. B. Stroup et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies
S. A. Stoch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?
Izabela Podgorski
FUTURE MEDICINAL CHEMISTRY (2009)
Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand
Wayne Balkan et al.
GENE (2009)
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Jacques Yves Gauthier et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts
Karen Fuller et al.
BONE (2008)
High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K
A. F. Schilling et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence
Wei Chen et al.
HUMAN MOLECULAR GENETICS (2007)
Emerging roles of cysteine cathepsins in disease and their potential as drug targets
Olga Vasiljeva et al.
CURRENT PHARMACEUTICAL DESIGN (2007)
A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys
S. Kumar et al.
BONE (2007)
Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity
Yin Xiao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
The consequences of lysosomotropism on the design of selective cathepsin K inhibitors
W. Cameron Black et al.
CHEMBIOCHEM (2006)
Human osteoblasts produce cathepsin K
J Mandelin et al.
BONE (2006)
Structure activity relationships of 5-, 6-, and 7-methyl -substituted azepan-3-one cathepsin K inhibitors
DS Yamashita et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
JJ Body et al.
CLINICAL CANCER RESEARCH (2006)
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity
JP Falgueyret et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Pharmacokinetics/pharmacodynamics of bisphosphonates - Use for optimisation of intermittent therapy for osteoporosis
SCLM Cremers et al.
CLINICAL PHARMACOKINETICS (2005)
Intracellular machinery for matrix degradation in bone-resorbing osteoclasts
J Vääräniemi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Cathepsin K mRNA and protein expression in prostate cancer progression
KD Brubaker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2002)
Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation
WS Hou et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Biosynthesis and processing of cathepsin K in cultured human osteoclasts
DJ Rieman et al.
BONE (2001)
Proteolysis of human bone collagen by cathepsin K: Characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope
LM Atley et al.
BONE (2000)
Share Paper
